PBL InterferonSource and Quansys Biosciences
Announce Alliance

New tools should benefit autoimmunity and infectious disease researchers

October 19, 2009, Piscataway, NJ and Logan, UT — PBL InterferonSource, the world’s premier manufacturer and distributor of interferons (IFNs) and related research products, and Quansys Biosciences, developer of protein arrays that assist in the understanding, diagnosis and treatment of disease, have entered into an agreement to broaden Quansys’ Q-Plex™ multiplex array offerings to enable the detection of interferons. The agreement will grant PBL international and limited US rights to sell Quansys Q-Plex™ multiplex array kits and related products.

The combination of Quansys Q-Plex™ multiplex arrays with PBL’s interferon reagents will allow researchers to examine the relationship of multiple interferons and cytokines simultaneously. Using this assay platform, researchers in autoimmunity and infectious disease can address key questions in drug development and clinical research. These include assessing cytokine profiles at various points throughout the course of disease, correlating alterations in cytokine profiles with patient responses to therapies, and determining off-target effects of drugs, all in an effort to predict clinical outcomes based on several biomarkers.

“Our alliance with Quansys will allow both companies to better serve the global research community. It will significantly reduce the time, effort and costs researchers expend in conducting their work,” stated Robert Pestka, PBL InterferonSource President and CEO. “This unique blend of cost-effective technology and interferon content should prove extremely beneficial to scientists developing the next generation of autoimmunity, viral, and cancer therapeutics.”

Matt Groll, General Manager at Quansys agreed, adding, “This relationship is an excellent blend of product, technology, and common corporate values. The pairing of PBL’s depth in the interferon field with our own Multiplex ELISA platform, Q-Plex™ technology, is a perfect fit. In addition, by leveraging PBL’s global distribution network we will be able to increase the exposure of Quansys’ products and better support researchers around the world.”

Quansys’ Q-Plex™ technology platform includes multiplex arrays, custom array services, a chemiluminescent imaging system and powerful analysis software enabling researchers to run multiplex arrays in their lab on a cost-effective proprietary system.

PBL InterferonSource offers the world’s largest selection of high-quality human and other mammal interferon-based products, including assay kits and reagents, IFN proteins, IFN monoclonal and polyclonal antibodies, and assay development services.

About Quansys Biosciences, Inc.

Quansys Biosciences, Inc., a Spendlove Research company, is dedicated to the development and manufacture of protein arrays to aide researchers and clinicians in better understanding, diagnosing, and treating disease through the development and application of a unique multiplex tool. Quansys specializes in custom planar-based arrays in numerous applications such as human health and research, veterinary diagnostics and seed genetics. Further information can be obtained at www.quansysbio.com.

About PBL InterferonSource

PBL InterferonSource, a division of Pestka Biomedical Laboratories, Inc., is the leading supplier of interferon research tools to the life science researcher. Founded in 1990 by Dr. Sidney Pestka, PBL is the company scientists turn to for their interferon-related needs: products, services, information and know-how. PBL products are available in over 80 countries worldwide through its distributor network, and PBL actively collaborates with companies working in the fields of autoimmune disease, inflammation, infectious disease, and cancer. With 200 years of combined interferon experience, PBL scientists strive to aid researchers around the world in our common quest to help humanity. For more information, visit www.interferonsource.com.

Safe Harbor Statement

Certain statements contained herein, including statements regarding development of the Companies’ products, services, markets, and future demands for the Companies’ products and services, and other statements regarding matters that are not historical facts, are forward-looking statements. Such forward-looking statements include risks and uncertainties; consequently, actual results may differ materially from those expressed or implied thereby.

Media Contacts

BL InterferonSource, Jaleel Shujath, (732) 777-9123, info@interferonsource.com
Quansys Biosciences, Inc., Matt Groll, (888) 782-6797, mgroll@quansysbio.com
Shaw & Todd Advertising and Marketing Communications, Chere Griffin, Account Executive, (908) 668- 1106 x15, cgriffin@shawtodd.com

##End##

Downloads are located at top of page.